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2805 
Revascularization Outcomes
Monday, March 31, 2008, 10:00 a.m.-11:30 a.m.
McCormick Place, Room S106a
10:00 a.m.
2805-3 Long-term Clinical Outcome After Implantation of Drug-
eluting Compared to Bare-metal Stents in a Real World 
Population: Three-year Results of the BASKET Trial
Christoph A. Kaiser, Hanspeter Brunner-La Rocca, Peter Buser, Fabian Nietlispach, 
Gregor Leibundgut, Franziska Bader, Matthias Pfisterer, BASKET Investigators, 
Department of Cardiology, University Hospital, Basel, Switzerland
Background: As compared to bare-metal stents (BMS), drug-eluting stents (DES) have 
been shown to reduce restenosis and target vessel revascularization (TVR) in pivotal 
trials with selected patients and simple lesions up to five years. The initial enthusiasm 
was recently tarnished by the findings of late and very late stent thrombosis after DES 
in real world registries and meta-analyses. The Basel Stent Kosteneffiktivitaets Trial 
(BASKET) was the first prospective randomized trial demonstrating an increased rate 
of clinical thrombosis associated events after DES compared to BMS up to 18 months 
(BASKET-LATE). It is unknown, whether these differences are maintained during long-
term follow-up.
Methods: A total of 826 patients treated by PCI/stenting within one year (May 05, 2003 
and May 31, 2004) were included and randomized to one of two DES (Cypher® , n=264 , 
Taxus®, n=264) or a cobalt-chromium-based BMS (Vision®, n=281). Excluded were only 
patients with in-stent-restenosis, vessel diameter >4mm or no consent. Patients were 
followed-up during 3 years for major adverse cardiac events, death, TVR, myocardial 
infarction and stent thrombosis. Patients were advised to stop clopidogrel after 6 months. 
The protocol did not allow control angiography without a clinical indication.
Results: The total population consisted of 79% men with an average age of 64+11 years 
presenting with stable angina in 42%, acute MI in 21% and unstable coronary syndromes 
in 36%. Patients had received 1.9+1.1 stents for a total stent length of 34+20mm per 
patient. There were no significant differences between the 3 patient groups in any of these 
parameters. The clinical follow-up up to 3 years will be completed by end of June 2007 
and the complete results including subgroup analyses will be available at the time of the 
ACC annual meeting 2008.
Conclusions: The 3 year clinical effectiveness findings from BASKET will demonstrate 
1) whether there is an ongoing trend for an increased rate of late thrombosis associated 
events after DES compared to BMS and 2) if yes, whether these events outweigh the 
benefits of DES regarding the reduction of restenosis.
10:15 a.m.
2805-4 Short- and Long-term Health Related Quality of Life 
and Anginal Status in Patients Treated for Multivessel 
Coronary Artery Disease: Insights Into the ARTS-II Trial
Ron T. van Domburg, Joost Daemen, Marie-Claude Morice, Bernard de Bruyne, Antonio 
Colombo, Carlos Macaya, Gert Richardt, Jaen Fajadet, Christian Hamm, Keith D. 
Dawkins, Pascal Franckx, Monique Schuijer, Kristel Wittebols, Magdaleen Pieters, Hans 
P. Stoll, Patrick W. Serruys, Erasmus Medical Center, Rotterdam, The Netherlands
Background: To determine the health related quality of life (HRQL) following sirolimus-
eluting stent (SES) (CYPHER®) implantation in patients with multivessel disease 
and to compare outcomes with the historical results of the two arms of the Arterial 
Revascularization Therapies Study (ARTS-I).
Methods: ARTS-II is a 45 center, single-arm study. The HRQL outcomes were compared 
to the outcome of the historical cohorts of the randomized ARTS-I trial using the same 
inclusion and exclusion criteria. Patients were stratified by clinical site to ensure that 
at least 1/3 had 3-vessel disease to achieve a number of treated lesions per patient 
comparable to ARTS-I. HRQL was evaluated at baseline, at 1- month and at 6-, 12- and 
36 months after revascularization using the Short Form Health Survey (SF-36) in patients 
treated with SES (n=585), BMS (n=483) or CABG (n=492).
Results: The corresponding participating rates varied from 100% at baseline to 93% at 
36 months. Both stenting and CABG resulted in significant improvement of HRQL and 
anginal status. There was a trend towards better HRQL after CABG than BMS beyond 
6 months. Already from the first month up to three years, SES patients had, on average, 
10% significant better HRQL than BMS patients on all HRQL subscales (p<0.01). Up to 
12 months the HRQL was better after SES than CABG and between 12 months and 36 
months the HRQL of SES and CABG were identical. At all time points, angina was more 
prevalent in the BMS group, whereas the incidence of angina was similar in the SES and 
CABG groups. At three years, 10% of the SES patients had angina, 13% of the CABG 
patients and 20% of the BMS patients.
Conclusions: Both stenting and CABG resulted in a significant improvement in HRQL 
and angina. With the introduction of the drug-eluting stents, with subsequent substantial 
reduction of restenosis, HRQL after SES was significantly improved as compared with 
BMS and was similar to CABG.
10:30 a.m.
2805-5 Four-Year Durability of Sirolimus-Eluting Stent in 
Patients With Unprotected Left Main Coronary Arteries 
Compared With Bare-Metal Stents: Multicenter Registry 
in Asia
Sunao Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan, Konyang 
University Hospital, Daejeon, South Korea
Aim: The aim of this study is to compare the safety and efficacy of Sirolimus-eluting 
stent (SES) and bare metal stent (BMS) on the outcome of patients with unprotected 
left main coronary arteries (LMT). Methods: Complete clinical follow-up to 4 years is 
being analyzed for 241 patients who received 120 SES and 121 BMS in patients with 
LMT (male 71.7%, mean age 70.5 yrs) in five high volume Asian centers. Lesion location 
of LMT was ostial 24 cases (10.0%), mid shaft 38 cases (15.8%) and distal 179 cases 
(74.3%). Results: The baseline clinical characteristics between 2 groups were similar. 
Angiographic and clinical success were achieved in all patients. At 4 years overall cardiac 
events occurred in 12.5% of SES patients and 38.0% of BMS patients (p<0.001). See 
figure. Conclusion: The use of Sirolimus-eluting stent is effective in preventing cardiac 
events compared with bare metal stent associated with low acute complication and these 
benefits is durable at least 4 years. 
10:45 a.m.
2805-6 Three-year Clinical Outcome After Primary Stenting of 
Totally Occluded Native Coronary Arteries: PRISON II 
Study
Braim M. Rahel, Maarten J. Suttorp, Gerrit J. Laarman, Jur M. ten Berg, Johannes C. 
Kelder, Mike A.R. Bosschaert, St Antonius Hospital, Nieuwegein, The Netherlands, 
Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
Background: The purpose of this study was to examine the three-year clinical outcome 
in patients enrolled in the Primary Stenting of Totally Occluded Native Coronary Arteries 
II (PRISON II) study. The PRISON II study was a prospective, randomized, single-blind, 2-
center study which demonstrated that sirolimus-eluting Cypher stents (SES) significantly 
improved both angiographic results (at 6 months) and clinical outcome (at 6 and 12 
months) compared with bare-metal BxVelocity stents (BMS).
Methods: Patients with chronic total occlusions in native coronary arteries randomized to 
either SES (100 patients) or BMS (100 patients) were followed clinically for three years.
Results: Between one and three years, there were infrequent additional clinical events 
that were equally distributed between the SES and BMS group. After three years, target 
lesion revascularization was 7% in the SES group versus 27% in the BMS group (p<0.001) 
and target vessel revascularization was seen in 11% in the SES group versus 30% in the 
BMS group (p=0.002). Major adverse cardiac events were noted in 10% of the SES group 
versus 34% in the BMS group (p<0.001). Target vessel failure was noted in 12% in the 
SES group versus 36% in the BMS group (p<0.001). There were no statistically significant 
differences in death, myocardial infarction, and stent thrombosis according to the ARC 
criteria between the two groups.
Conclusion: Clinical outcome up to three years after implantation of SES for total 
coronary occlusions continue to demonstrate a significant reduction in adverse clinical 
events compared with BMS without the evidence for either disproportionate late restenosis 
or late stent thrombosis.
11:00 a.m.
2805-7 Very Long-term Clinical Outcomes of the DESIRE (Drug 
Eluting Stents In the REal world) Registry
Jose de Ribamar Costa, Jr., Amanda Sousa, Ricardo Costa, Adriana Moreira, Manuel 
Cano, Galo Maldonado, Marcos Barbosa, Maria Helena Bib, Rodolfo Staico, J Eduardo 
Sousa, Hospital do Coração - Associação do Sanatório Sírio, São Paulo, Brazil
Background: Drug-eluting stents (DES) have markedly reduced the need of repeat 
intervention in the treated lesion of selected patients. However, very long-term efficacy 
and safety of these new devices for the treatment of “real-world” pts is still unclear. 
Methods: The DESIRE registry is a non-randomized single-center registry with 
consecutive pts treated solely with DES between May 2002 and May 2007. The primary 
end point was long-term occurrence of MACE and stent thrombosis (ST). Pts were 
clinically evaluated at 1, 3 and 6 months and then annually up to 5 years. ARC definition 
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Results: A total of 2,081 patients (2,864 lesions and 3,120 stents) were included. The 
mean age was 63 years with 29% of diabetics. Mean reference vessel diameter and 
lesion length were 2.76±0.47mm and 16.3±8.2mm respectively. Procedural success was 
achieved in 98.5% of the cases. Follow-up was obtained in 96.5% of the patients. In the 
long-term follow-up, TLR was performed in 3.3% of the patients. Q-wave MI occurred in 
only 0.7% of these patients and total ST rate was 1.6% (n=33) with 17 cases (51.5%) 
classified as definite. The figure shows the survival-free of MACE curve up to 5 years. 
Cox’s multivariate analysis showed treatment of acute myocardial infarction, lesion 
calcification, residual stenosis and stent length as independent predictors of ST.
Conclusion: The use of DES in an unselected population is associated with long-term 
safety and effectiveness with acceptable low rates of adverse clinical events. 
11:15 a.m.
2805-8 Risk of Death or Emergency Cardiac Surgery in 
Contemporary Elective Percutaneous Coronary 
Interventions; Implications for Percutaneous Coronary 
Interventions Without Onsite Bypass Surgery
Hitinder S. Gurm, Dean E. Smith, Eva Kline-Rogers, Share David, Michael O’Donnell, 
Richard McNamara, Mauro Moscucci, University of Michigan Medical Center, Ann Arbor, MI
Background: There is ongoing debate on the safety of elective percutaneous coronary 
intervention (PCI) without onsite surgical backup. There are, however, limited data 
on the frequency of need for emergency coronary artery bypass surgery (CABG) in 
contemporary elective PCI.
Methods: We evaluated the incidence and predictors of emergency CABG and mortality 
among patients undergoing elective PCI in a large regional consortium.
Results: Our cohort comprised of 53,940 patients who underwent elective PCI at 
19 hospitals in Michigan between1997 and 2006 A total of 143 (0.27%) patients 
needed emergency CABG while 97 (0.18%) died during the index hospitalization. The 
independent predictors of mortality were age > 80 years (OR 5.04), age 70-79 years (OR 
3.07), female gender (OR 2.01), history of dialysis dependent renal failure (OR 3.82), 
history of prior CABG (OR 0.32), history of chronic obstructive pulmonary disease (OR 
2.22), three vessel disease (OR 2.11),and intervention on three or more lesions (OR 
2.86). The independent predictors of emergency CABG were prior history of CABG (OR 
0.07), prior history of PCI (OR 0.56), three vessel disease (OR 2.96) and calcified lesion 
(OR 2.27). In patients with no prior history of coronary revascularization, the presence of 
coronary artery calcification and 3 vessel disease was associated with a 2.12% incidence 
of emergency CABG and a 1.16% mortality rate, when compared to an emergency CABG 
rate of 0.28% and a mortality rate of 0.1% in patients without these adverse angiographic 
characteristics.
Conclusion: The incidence of emergency CABG and in-hospital mortality in elective 
PCI is low but not insignificant. Adverse angiographic characteristics identify patients at 
extremely high risk of emergency CABG and in hospital mortality. These finding might 
have important implications in the selection of patients for elective PCI in centers without 
on site cardiac surgery.
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